

1 **ACGME Program Requirements for Graduate Medical Education**
2 **in Allergy and Immunology**

3
4 **Common Program Requirements are in BOLD**

5
6 Effective: July 1, 2007
7

8 **Introduction**

9
10 **Int.A. Residency is an essential dimension of the transformation of the medical**
11 **student to the independent practitioner along the continuum of medical**
12 **education. It is physically, emotionally, and intellectually demanding, and**
13 **requires longitudinally-concentrated effort on the part of the resident.**
14

15 **The specialty education of physicians to practice independently is**
16 **experiential, and necessarily occurs within the context of the health care**
17 **delivery system. Developing the skills, knowledge, and attitudes leading to**
18 **proficiency in all the domains of clinical competency requires the resident**
19 **physician to assume personal responsibility for the care of individual**
20 **patients. For the resident, the essential learning activity is interaction with**
21 **patients under the guidance and supervision of faculty members who give**
22 **value, context, and meaning to those interactions. As residents gain**
23 **experience and demonstrate growth in their ability to care for patients, they**
24 **assume roles that permit them to exercise those skills with greater**
25 **independence. This concept—graded and progressive responsibility—is**
26 **one of the core tenets of American graduate medical education.**
27 **Supervision in the setting of graduate medical education has the goals of**
28 **assuring the provision of safe and effective care to the individual patient;**
29 **assuring each resident’s development of the skills, knowledge, and**
30 **attitudes required to enter the unsupervised practice of medicine; and**
31 **establishing a foundation for continued professional growth.**
32

33 ~~Int.B. Definition and Scope of the Specialty~~

34
35 ~~Int.B.1. Graduate medical education programs in allergy and immunology should prepare~~
36 ~~Allergy and immunology specialists to provide expert medical care for patients~~
37 ~~with allergic and immunologic disorders. These specialists may serve as~~
38 ~~consultants, educators, and physician scientists in asthma, allergic disorders,~~
39 ~~immunologic disorders, and immunodeficiency diseases.~~
40

41 ~~Int.B.2. Residents in this specialty have specific competencies in the care of~~
42 ~~patients of all ages.~~
43

44 ~~Int.C. Duration and Scope of Education~~

45
46 ~~Int.C.1. The length of the educational program in allergy and immunology must be is 24~~
47 ~~months in length of full-time education. The Review Committee recognizes that~~
48 ~~this may be accomplished in two ways: 24 consecutive months of education, or~~
49 ~~over 36 months that includes a total of 24 months of allergy and immunology~~
50 ~~education.~~
51

52 ~~Int.C.2. Residents must demonstrate competencies in treating children and adults~~
53 ~~with asthma, allergic disorders, immunologic disorders, and~~
54 ~~immunodeficiency diseases.~~

56 ~~Int.C.3. Residents must satisfy the requirements for program completion with 24~~
57 ~~months of education. The Review Committee recognizes this may be~~
58 ~~accomplished in two ways: 24 consecutive months of education, or time~~
59 ~~spread out over 36 months that includes a total of 24 months of allergy~~
60 ~~and immunology education. The program must meet the requirements~~
61 ~~outlined in section IV.~~

63 **I. Institutions**

64
65 **I.A. Sponsoring Institution**

66
67 **One sponsoring institution must assume ultimate responsibility for the**
68 **program, as described in the Institutional Requirements, and this**
69 **responsibility extends to resident assignments at all participating sites.**

70
71 **The sponsoring institution and the program must ensure that the program**
72 **director has sufficient protected time and financial support for his or her**
73 **educational and administrative responsibilities to the program.**

74
75 I.A.1. ~~Allergy and immunology programs should be conducted principally in~~
76 ~~institutions with ACGME-accredited graduate medical education~~
77 ~~programs in both pediatrics and internal medicine. Programs may be~~
78 ~~based in institutions with ACGME-accredited internal medicine or~~
79 ~~pediatrics training programs that collaborate with participating institutions~~
80 ~~that have accredited GME programs in other relevant specialties.~~

81
82 I.A.2. ~~The sponsoring institution must ensure sufficient faculty, financial~~
83 ~~resources, clinical resources, research opportunities, and library facilities~~
84 ~~to meet the residents' educational needs and to enable the program to~~
85 ~~comply with accreditation requirements.~~

86
87 **I.B. Participating Sites**

88
89 **I.B.1. There must be a program letter of agreement (PLA) between the**
90 **program and each participating site providing a required**
91 **assignment. The PLA must be renewed at least every five years.**

92
93 **The PLA should:**

94
95 **I.B.1.a) identify the faculty who will assume both educational and**
96 **supervisory responsibilities for residents;**

97
98 **I.B.1.b) specify their responsibilities for teaching, supervision, and**
99 **formal evaluation of residents, as specified later in this**
100 **document;**

101 **I.B.1.c) specify the duration and content of the educational**
102 **experience; and,**

- 103
104 **I.B.1.d)** state the policies and procedures that will govern resident
105 education during the assignment.
106
- 107 I.B.1.e) ~~outline the educational goals and objectives to be attained by the~~
108 ~~resident during the assignment.~~
109
- 110 **I.B.2.** The program director must submit any additions or deletions of
111 participating sites routinely providing an educational experience,
112 required for all residents, of one month full time equivalent (FTE) or
113 more through the Accreditation Council for Graduate Medical
114 Education (ACGME Accreditation Data System (ADS)).
115
- 116 I.B.3. ~~Assignments at participating sites must be of sufficient length to ensure a~~
117 ~~quality educational experience and should provide sufficient opportunity~~
118 ~~for continuity of care. All participating institutions must demonstrate the~~
119 ~~ability to promote the program goals and educational and peer activities.~~
120 ~~Exceptions must be justified and approved in advance.~~
121
- 122 I.B.4. Resident education at a ~~private practitioner's office participating site that~~
123 ~~is a private practitioner's office must be limited to those offices of program~~
124 faculty members and must have defined goals and objectives.
125
- 126 I.B.4.a) ~~must emphasize that the resident is gaining an educational~~
127 ~~experience, not providing service to the office. The goals,~~
128 ~~objectives and manner of supervision must be documented;~~
129
- 130 I.B.4.b) ~~should be one that cannot be met in any other participating~~
131 ~~institution; and,~~
132
- 133 I.B.4.c) ~~requires that the participating private office practitioner be listed~~
134 ~~on the Program Information Form (PIF) as a member of the~~
135 ~~faculty.~~
136
- 137 **II. Program Personnel and Resources**
138
- 139 **II.A. Program Director**
140
- 141 **II.A.1.** There must be a single program director with authority and
142 accountability for the operation of the program. The sponsoring
143 institution's GMEC must approve a change in program director.
144 After approval, the program director must submit this change to the
145 ACGME via the ADS.
146
- 147 **II.A.2.** The program director should continue in his or her position for a
148 length of time adequate to maintain continuity of leadership and
149 program stability.
150
- 151 **II.A.3.** Qualifications of the program director must include:
152
- 153 **II.A.3.a)** requisite specialty expertise and documented educational

- 154 and administrative experience acceptable to the Review
 155 Committee;
 156
- 157 **II.A.3.b)** current certification in the specialty by the American Board of
 158 Allergy and Immunology, or specialty qualifications that are
 159 acceptable to the Review Committee;
 160
- 161 **II.A.3.c)** current medical licensure and appropriate medical staff
 162 appointment;
 163
- 164 **II.A.3.c).(1)** Physician faculty members must have a valid unrestricted
 165 license to practice medicine in the state jurisdiction where
 166 the program's institutional sponsor is located. Program
 167 directors in certain federal programs are exempted from
 168 the requirement to be licensed in the sponsoring
 169 institution's state.
 170
- 171 **II.A.3.d)** at least three years' of participation as an active faculty member in
 172 an ACGME-accredited allergy and immunology program or
 173 possess qualifications acceptable to the Review Committee; and,
 174
- 175 **II.A.3.e)** leadership qualities and sufficient time and effort devoted to the
 176 program to provide day-to-day continuity of leadership and to fulfill
 177 all of the responsibilities of meeting the educational goals of the
 178 program; and,
 179
- 180 **II.A.4.** **The program director must administer and maintain an educational**
 181 **environment conducive to educating the residents in each of the**
 182 **ACGME competency areas. The program director must:**
 183
- 184 **II.A.4.a)** oversee and ensure the quality of didactic and clinical
 185 education in all institutions that participate in the program;
 186
- 187 **II.A.4.b)** approve a local director at each participating site who is
 188 accountable for resident education;
 189
- 190 **II.A.4.c)** approve the selection of program faculty as appropriate;
 191
- 192 **II.A.4.d)** evaluate program faculty and approve the continued
 193 participation of program faculty based on evaluation;
 194
- 195 **II.A.4.e)** monitor resident supervision at all participating sites;
 196
- 197 **II.A.4.f)** prepare and submit all information required and requested by
 198 the ACGME, including but not limited to the program
 199 information forms and annual program resident updates to
 200 the ADS, and ensure that the information submitted is
 201 accurate and complete;
 202
- 203 **II.A.4.g)** provide each resident with documented semiannual
 204 evaluation of performance with feedback;

205		
206	II.A.4.h)	ensure compliance with grievance and due process
207		procedures as set forth in the Institutional Requirements and
208		implemented by the sponsoring institution;
209		
210	II.A.4.i)	provide verification of residency education for all residents,
211		including those who leave the program prior to completion;
212		
213	II.A.4.j)	implement policies and procedures consistent with the
214		institutional and program requirements for resident duty
215		hours and the working environment, including moonlighting,
216		and, to that end, must:
217		
218	II.A.4.j).(1)	distribute these policies and procedures to the
219		residents and faculty;
220		
221	II.A.4.j).(2)	monitor resident duty hours, according to sponsoring
222		institutional policies, with a frequency sufficient to
223		ensure compliance with ACGME requirements;
224		
225	II.A.4.j).(3)	adjust schedules as necessary to mitigate excessive
226		service demands and/or fatigue; and,
227		
228	II.A.4.j).(4)	if applicable, monitor the demands of at-home call and
229		adjust schedules as necessary to mitigate excessive
230		service demands and/or fatigue.
231		
232	II.A.4.k)	monitor the need for and ensure the provision of back up
233		support systems when patient care responsibilities are
234		unusually difficult or prolonged;
235		
236	II.A.4.l)	comply with the sponsoring institution's written policies and
237		procedures, including those specified in the Institutional
238		Requirements, for selection, evaluation and promotion of
239		residents, disciplinary action, and supervision of residents;
240		
241	II.A.4.m)	be familiar with and comply with ACGME and Review
242		Committee policies and procedures as outlined in the ACGME
243		Manual of Policies and Procedures;
244		
245	II.A.4.n)	obtain review and approval of the sponsoring institution's
246		GMEC/DIO before submitting to the ACGME information or
247		requests for the following:
248		
249	II.A.4.n).(1)	all applications for ACGME accreditation of new
250		programs;
251		
252	II.A.4.n).(2)	changes in resident complement;
253		
254	II.A.4.n).(3)	major changes in program structure or length of
255		training;

256		
257	II.A.4.n).(4)	progress reports requested by the RC;
258		
259	II.A.4.n).(5)	responses to all proposed adverse actions;
260		
261	II.A.4.n).(6)	requests for increases or any change to resident duty hours;
262		
263		
264	II.A.4.n).(7)	voluntary withdrawals of ACGME-accredited programs;
265		
266		
267	II.A.4.n).(8)	requests for appeal of an adverse action;
268		
269	II.A.4.n).(9)	appeal presentations to a Board of Appeal or the ACGME; and,
270		
271		
272	II.A.4.n).(10)	proposals to ACGME for approval of innovative educational approaches.
273		
274		
275	II.A.4.o)	obtain DIO review and co-signature on all program information forms, as well as any correspondence or document submitted to the ACGME that addresses:
276		
277		
278		
279	II.A.4.o).(1)	program citations, and/or
280		
281	II.A.4.o).(2)	request for changes in the program that would have significant impact, including financial, on the program or institution.
282		
283		
284		
285	II.A.4.p)	be responsible for ongoing communications with the American Board of Allergy and Immunology. This includes completing interim and final evaluations;
286		
287		
288		
289	II.A.4.q)	If an extension of more than three months in the educational program is necessary, the program director must notify the Review Committee of the extension.
290		
291		
292		
293	II.A.4.q).(1)	The program director must describe the proposed curriculum for that resident and the measures taken to minimize the impact on other residents. Any changes in rotation schedules should be included in the notification.
294		
295		
296		
297		
298	II.A.4.q).(2)	Express permission must be obtained in advance from the Review Committee if the extension is greater than three months.
299		
300		
301		
302	II.B.	Faculty
303		
304	II.B.1.	At each participating site, there must be a sufficient number of faculty with documented qualifications to instruct and supervise all residents at that location.
305		
306		

- 307
308 II.B.1.a) Each program must have at least two key-clinical core faculty
309 members.
310
311 II.B.1.a).(1) Key Core faculty members must be certified by the
312 American Board of Allergy and Immunology or possess
313 qualifications acceptable to the Review Committee. These
314 faculty members must devote ~~a minimum of 10% effort at~~
315 least 15 hours per week to ~~A/allergy and immunology~~
316 resident education training, ~~and can include the Program~~
317 Director.
318
319 II.B.1.a).(2) At least one key-core faculty member must be a qualified
320 allergist and immunologist who has completed an ACGME-
321 or Royal College of Physicians and Surgeons of Canada
322 (RCPSC)-accredited residency in pediatrics.
323
324 II.B.1.a).(3) At least one key-core faculty member must be a qualified
325 allergist and immunologist who has completed an ACGME-
326 or Royal College of Physicians and Surgeons of Canada
327 (RCPSC)-accredited residency in internal medicine.
328
329 **The faculty must:**
330
331 **II.B.1.b) devote sufficient time to the educational program to fulfill**
332 **their supervisory and teaching responsibilities; and to**
333 **demonstrate a strong interest in the education of residents,**
334 **and**
335
336 **II.B.1.c) administer and maintain an educational environment**
337 **conducive to educating residents in each of the ACGME**
338 **competency areas.**
339
340 **II.B.2. The physician faculty must have current certification in the specialty**
341 **by the American Board of Allergy and Immunology, or possess**
342 **qualifications acceptable to the Review Committee.**
343
344 II.B.2.a) ~~The faculty must include:~~
345
346 II.B.2.b) ~~qualified allergist(s) and immunologist(s) having residency training~~
347 ~~in internal medicine, and who are assigned to a participating site;~~
348
349 II.B.2.c) ~~qualified allergist(s) and immunologist(s) having residency training~~
350 ~~in pediatrics, and who are assigned to a participating site;~~
351
352 II.B.2.c).(1) ~~a faculty member who is residency trained in both internal~~
353 ~~medicine and pediatrics may fulfill the requirements in~~
354 ~~either Section II.B.2.a or II.B.2.b.~~
355
356 **II.B.3. The physician faculty must possess current medical licensure and**
357 **appropriate medical staff appointment.**

- 358
359 **II.B.4.** **The nonphysician faculty must have appropriate qualifications in**
360 **their field and hold appropriate institutional appointments.**
361
- 362 **II.B.5.** **The faculty must establish and maintain an environment of inquiry**
363 **and scholarship with an active research component.**
364
- 365 **II.B.5.a)** **The faculty must regularly participate in organized clinical**
366 **discussions, rounds, journal clubs, and conferences.**
367
- 368 **II.B.5.b)** **Some members of the faculty should also demonstrate**
369 **scholarship by one or more of the following:**
370
- 371 **II.B.5.b).(1)** **peer-reviewed funding;**
372
- 373 **II.B.5.b).(2)** **publication of original research or review articles in**
374 **peer-reviewed journals, or chapters in textbooks;**
375
- 376 **II.B.5.b).(3)** **publication or presentation of case reports or clinical**
377 **series at local, regional, or national professional and**
378 **scientific society meetings; or,**
379
- 380 **II.B.5.b).(4)** **participation in national committees or educational**
381 **organizations.**
382
- 383 **II.B.5.c)** **Faculty should encourage and support residents in scholarly**
384 **activities.**
385
- 386 **II.B.6.** ~~All regularly participating faculty must be included in the PIF, with~~
387 ~~delineation of the number of hours spent in the education program.~~
388
- 389 **II.B.7.** ~~The Physician faculty members must demonstrate competence in both~~
390 ~~clinical care and teaching abilities.~~
391
- 392 **II.B.8.** ~~Physician faculty members who are not specialists in allergy and~~
393 ~~immunology must be certified in their specialties by the appropriate~~
394 ~~American Board of Medical Specialties (ABMS) board or the RCPSC, in~~
395 ~~their specialty or have equivalent qualifications. or possess qualifications~~
396 ~~that are acceptable to the Review Committee.~~
397
- 398 **II.B.9.** ~~The faculty must actively pursue scholarly activity in allergy and~~
399 ~~immunology and encourage residents to engage in scholarly activity.~~
400
- 401 **II.C.** **Other Program Personnel**
402
- 403 **The institution and the program must jointly ensure the availability of all**
404 **necessary professional, technical, and clerical personnel for the effective**
405 **administration of the program.**
406
- 407 **II.C.1.** **All other program personnel faculty, such as including health care**
408 **providers and scientists, must be appropriately qualified in their area of**

- 409 expertise.
- 410
- 411 **II.D. Resources**
- 412
- 413 **The institution and the program must jointly ensure the availability of**
- 414 **adequate resources for resident education, as defined in the specialty**
- 415 **program requirements.**
- 416
- 417 II.D.1. The program must provide a sufficient number of pediatric and adult
- 418 patients to provide education in asthma, allergic disorders, immunologic
- 419 disorders, and immunodeficiency diseases.
- 420
- 421 II.D.2. A sufficient number of adult and pediatric ambulatory patients must be
- 422 provided for each resident during the 24-month program.
- 423
- 424 **II.E. Medical Information Access**
- 425
- 426 **Residents must have ready access to specialty-specific and other**
- 427 **appropriate reference material in print or electronic format. Electronic**
- 428 **medical literature databases with search capabilities should be available.**
- 429
- 430 **III. Resident Appointments**
- 431
- 432 **III.A. Eligibility Criteria**
- 433
- 434 **The program director must comply with the criteria for resident eligibility**
- 435 **as specified in the Institutional Requirements.**
- 436
- 437 III.A.1. ~~Prior to appointment in the program, residents must~~ Residents admitted
- 438 ~~to allergy and immunology programs have successfully completed a~~
- 439 ~~program in an~~ internal medicine or pediatrics residency program
- 440 ~~accredited by the Accreditation Council for Graduate Medical Education~~
- 441 ~~(ACGME) or the RCPSC.~~
- 442
- 443 III.A.2. ~~Before entry into~~ Prior to appointment in the program, each resident must
- 444 be notified in writing of the required length of the ~~allergy and immunology~~
- 445 ~~educational program.~~
- 446
- 447 **III.B. Number of Residents**
- 448
- 449 **The program director may not appoint more residents than approved by the**
- 450 **Review Committee, unless otherwise stated in the specialty-specific**
- 451 **requirements. The program's educational resources must be adequate to**
- 452 **support the number of residents appointed to the program.**
- 453
- 454 III.B.1. ~~The Review Committee for Allergy and Immunology does not approve a~~
- 455 ~~specific number of resident positions. At the time of program review, the~~
- 456 ~~Committee will judge the adequacy of the program's resources to support~~
- 457 ~~the number of resident positions proposed.~~
- 458
- 459 **III.C. Resident Transfers**

- 460
461 **III.C.1. Before accepting a resident who is transferring from another**
462 **program, the program director must obtain written or electronic**
463 **verification of previous educational experiences and a summative**
464 **competency-based performance evaluation of the transferring**
465 **resident.**
466
- 467 **III.C.1.a)** ~~Resident transfers must be reported to the Review Committee and~~
468 ~~the American Board of Allergy and Immunology. The transfer~~
469 ~~document should include an assessment of competencies in the~~
470 ~~six areas described in Section IV.5.~~
471
- 472 **III.C.2. A program director must provide timely verification of residency**
473 **education and summative performance evaluations for residents**
474 **who leave the program prior to completion.**
475
- 476 **III.D. Appointment of Fellows and Other Learners**
477
- 478 **The presence of other learners (including, but not limited to, residents from**
479 **other specialties, subspecialty fellows, PhD students, and nurse**
480 **practitioners) in the program must not interfere with the appointed**
481 **residents' education. The program director must report the presence of**
482 **other learners to the DIO and GMEC in accordance with sponsoring**
483 **institution guidelines.**
484
- 485 **IV. Educational Program**
486
- 487 **IV.A. The curriculum must contain the following educational components:**
488
- 489 **IV.A.1. Overall educational goals for the program, which the program must**
490 **distribute to residents and faculty annually;**
491
- 492 **IV.A.2. Competency-based goals and objectives for each assignment at**
493 **each educational level, which the program must distribute to**
494 **residents and faculty annually, in either written or electronic form.**
495 **These should be reviewed by the resident at the start of each**
496 **rotation;**
497
- 498 **IV.A.3. Regularly scheduled didactic sessions;**
499
- 500 **IV.A.3.a)** ~~attendance at~~ Didactic sessions must include regularly scheduled
501 conferences, lectures, journal clubs, or seminars; ~~and, reading~~
502 ~~and preparation for teaching assignments;~~
503
- 504 **IV.A.3.a).(1)** Residents must attend at least 70% of required didactic
505 sessions.
506
- 507 **IV.A.3.b)** Required core didactic topics must include: ~~must study asthma,~~
508 ~~allergic disorders, immunologic disorders, and immunodeficiency~~
509 ~~diseases. must have a structured curriculum in~~
510

511	IV.A.3.b).(1)	pathophysiology, diagnosis, differential diagnosis,
512		complications, and treatment of the following diseases and
513		circumstances:
514		
515	IV.A.3.b).(1).(a)	anaphylaxis, asthma, atopic dermatitis, contact
516		dermatitis, drug allergy, food allergy, rhinitis and
517		nasal polyps, sinusitis, stinging insect sensitivity,
518		ocular allergy, acute and chronic
519		urticaria/angioedema, <u>and</u> hereditary and acquired
520		angioedema;
521		
522	IV.A.3.b).(1).(b)	primary immunodeficiency, <u>to include</u> humoral
523		defects, cellular defects, phagocytic defects,
524		complement defects, and other genetic defects;
525		
526	IV.A.3.b).(1).(c)	acquired immunodeficiency, <u>to include</u> : malignancy,
527		infectious causes, <u>and</u> nutritional/metabolic causes;
528		<u>and</u> .
529		
530	IV.A.3.b).(1).(d)	autoimmune diseases, allergic bronchopulmonary
531		aspergillosis, eosinophilic disorders,
532		hypersensitivity pneumonitis, mastocytosis,
533		occupational lung disease, vasculitis,
534		autoinflammatory disorders (<u>e.g., Familial</u>
535		<u>Mediterranean Fever, TRAPS, Hyper-IgD</u>), <u>and</u>
536		cystic fibrosis.
537		
538	IV.A.3.b).(2)	<u>basic science knowledge and principles related to</u>
539		<u>diagnostic testing and treatment modalities, including:</u>
540		
541	IV.A.3.b).(2).(a)	allergens -aerobiology, to include identification of
542		relevant allergens;
543		
544	IV.A.3.b).(2).(b)	allergen measurement <u>and</u> environmental controls;
545		
546	IV.A.3.b).(2).(c)	allergen extracts, <u>to include</u> preparation,
547		standardization, prescription writing, <u>and</u>
548		administration;
549		
550	IV.A.3.b).(2).(d)	pharmacology, <u>to include</u> mechanisms of action,
551		pharmacokinetics, drug development, drug
552		metabolism, drug interactions, drug side effects,
553		<u>and</u> preparation and use of monoclonal antibodies;
554		
555	IV.A.3.b).(2).(e)	diagnostic testing of allergic diseases, <u>to include</u>
556		sensitivity and specificity, cost, immediate
557		hypersensitivity skin testing, patch testing, in vitro
558		testing, <u>and</u> specialty laboratory testing;
559		
560	IV.A.3.b).(2).(f)	special types of skin testing (<u>e.g., to include</u>
561		physical urticaria; <u>and</u> autologous skin tests);

562		
563	IV.A.3.b).(2).(g)	nasal cytology, rhinoscopy, skin biopsies, <u>and</u> food challenge testing;
564		
565		
566	IV.A.3.b).(2).(h)	other necessary components of the curriculum, pulmonary physiology and testing pulmonary function testing, including <u>to include</u> methods and reliability, <u>and</u> provocation challenges for bronchial reactivity;
567		
568		
569		
570		
571		
572	IV.A.3.b).(2).(i)	diagnostic testing, of clinical immunology diseases <u>that include</u> <u>to include</u> :
573		
574		
575	IV.A.3.b).(2).(i).(i)	principles and techniques of clinical immunology laboratory procedures;
576		
577		
578	IV.A.3.b).(2).(i).(ii)	tests for humoral immunity, tests for cellular immunity, neutrophil function, cytokines, immune complexes, cryoprecipitable proteins, total serum complement activity and individual components, histocompatibility, tests for acquired immunodeficiencies, tests for autoimmunity and vasculitis; <u>and</u> ,
579		
580		
581		
582		
583		
584		
585		
586		
587	IV.A.3.b).(2).(i).(iii)	preparation and use of monoclonal antibodies;
588		
589		
590	IV.A.3.b).(2).(j)	intravenous immunoglobulins, <u>to include</u> mechanism of action, pharmacological properties, administration, development, contraindications and side effects, <u>and cost</u> ; <u>and</u> ,
591		
592		
593		
594		
595	IV.A.3.b).(2).(k)	vaccines and immunotherapies, <u>to include</u> mechanism of action, administration, development, contraindications and side effects, tests for vaccine response, <u>and</u> use in immunodeficiencies.
596		
597		
598		
599		
600	IV.A.3.b).(3)	other basic science and other areas important to clinical practice, including:
601		
602		
603	IV.A.3.b).(3).(a)	immunology, <u>to include</u> transplantation, gastrointestinal, skin, reproductive, endocrine, tumor, <u>and</u> molecular/immunobiology;
604		
605		
606		
607	IV.A.3.b).(3).(b)	diagnostic imaging;
608		
609	IV.A.3.b).(3).(c)	mechanisms of inflammation;
610		
611	IV.A.3.b).(3).(d)	knowledge of controversial or unproven drug or therapeutic techniques in allergy asthma allergic
612		

613		disorders, immunologic disorders, and
614		immunodeficiency diseases;
615		
616	IV.A.3.b).(3).(e)	ethics, to include <u>acquire a working knowledge of</u>
617		research ethics and principles of confidentiality;
618		
619	IV.A.3.b).(3).(f)	psychological effects of chronic illness;
620		
621	IV.A.3.b).(3).(g)	practice management insurance, coding, billing,
622		patient satisfaction, malpractice, healthcare politics;
623		<u>and,</u>
624		
625	IV.A.3.b).(3).(h)	costs of therapy and diagnostic testing.
626		
627	IV.A.4.	Delineation of resident responsibilities for patient care, progressive
628		responsibility for patient management, and supervision of residents
629		over the continuum of the program; and,
630		
631	IV.A.5.	ACGME Competencies
632		
633		The program must integrate the following ACGME competencies
634		into the curriculum:
635		
636	IV.A.5.a)	Patient Care
637		
638		Residents must be able to provide patient care that is
639		compassionate, appropriate, and effective for the treatment of
640		health problems and the promotion of health. Residents:
641		
642	IV.A.5.a).(1)	must demonstrate proficiency in: the following allergy and
643		immunology specific competencies to begin the
644		independent practice of this specialty;
645		
646	IV.A.5.a).(1).(a)	must conduct <u>conducting</u> comprehensive and
647		detailed medical interviews with children and adults
648		who present suspected allergic and/or immunologic
649		disorders;
650		
651	IV.A.5.a).(1).(b)	must perform <u>performing</u> a physical examination
652		appropriate to the specialty;
653		
654	IV.A.5.a).(1).(c)	must select, perform, and interpret <u>selecting,</u>
655		<u>performing, and interpreting the results of</u>
656		diagnostic tests and studies; <u>and,</u>
657		
658	IV.A.5.a).(1).(d)	must assess <u>assessing</u> the risks and benefits of
659		allergic and immunologic disorder therapies,
660		<u>including</u> (e.g., drug therapy, allergen
661		immunotherapy, immunomodulatory therapy);
662		
663	IV.A.5.a).(2)	must counsel and educate patients about diagnosis,

664		prognosis, and treatment;
665		
666	IV.A.5.a).(3)	must consult with and educate other physicians and health care providers;
667		
668		
669	IV.A.5.a).(4)	must apply basic and clinical science to the clinical care of patients;
670		
671		
672	IV.A.5.a).(5)	must coordinate including the use of consultation;
673		
674	IV.A.5.a).(6)	must analyze medical and other scientific literature;
675		
676	IV.A.5.a).(7)	ensure that residents have formal instruction and, clinical experience with, as well as <u>must demonstrate proficiency in performing and evaluating, to the satisfaction of the program director or designated faculty member, and at least five times per procedure, results for each of the following:</u> These procedures must be entered into the ACGME Resident Case Log System: These procedures are required by the American Board of Allergy and Immunology for certification.
677		
678		
679		
680		
681		
682		
683		
684		
685		
686	IV.A.5.a).(7).(a)	allergen immunotherapy;
687		
688	IV.A.5.a).(7).(b)	drug desensitization and challenge <u>hypersensitivity diagnosis and treatment;</u>
689		
690		
691	IV.A.5.a).(7).(c)	immediate hypersensitivity skin testing;
692		
693	IV.A.5.a).(7).(d)	<u>immunoglobulin treatment and/or other immunomodulator therapies;</u>
694		
695		
696	IV.A.5.a).(7).(e)	IVIg treatment and administration
697		
698	IV.A.5.a).(7).(f)	pulmonary function tests <u>ing;</u>
699		
700	IV.A.5.a).(7).(g)	Physical urticaria testing
701		
702	IV.A.5.a).(7).(h)	food challenge testing <u>hypersensitivity diagnosis and treatment; and,</u>
703		
704		
705	IV.A.5.a).(8)	ensure that residents have proficiency with the following procedures:
706		
707		
708	IV.A.5.a).(8).(a)	<u>contact or delayed hypersensitivity skin testing,</u>
709		
710	IV.A.5.a).(8).(b)	Provocation testing for hyper-reactive airways
711		
712	IV.A.5.a).(8).(c)	Nasal cytology
713		
714	IV.A.5.a).(8).(d)	Patch testing

715		
716	IV.A.5.a).(8).(e)	Rhinolaryngoscopy
717		
718	IV.A.5.a).(9)	<u>must enter all required procedures into the ACGME</u>
719		<u>Resident Case Log System.</u>
720		
721	IV.A.5.b)	Medical Knowledge
722		
723		Residents must demonstrate knowledge of established and
724		evolving biomedical, clinical, epidemiological and social-
725		behavioral sciences, as well as the application of this
726		knowledge to patient care. Residents:
727		
728	IV.A.5.b).(1)	<u>must demonstrate proficiency in their knowledge of all</u>
729		<u>required core didactic topics through performance in</u>
730		<u>objective examinations and application to patient care.</u>
731		
732	IV.A.5.c)	Practice-based Learning and Improvement
733		
734		Residents must demonstrate the ability to investigate and
735		evaluate their care of patients, to appraise and assimilate
736		scientific evidence, and to continuously improve patient care
737		based on constant self-evaluation and life-long learning.
738		Residents are expected to develop skills and habits to be able
739		to meet the following goals:
740		
741	IV.A.5.c).(1)	identify strengths, deficiencies, and limits in one’s
742		knowledge and expertise;
743		
744	IV.A.5.c).(2)	set learning and improvement goals;
745		
746	IV.A.5.c).(3)	identify and perform appropriate learning activities;
747		
748	IV.A.5.c).(4)	systematically analyze practice using quality
749		improvement methods, and implement changes with
750		the goal of practice improvement;
751		
752	IV.A.5.c).(5)	incorporate formative evaluation feedback into daily
753		practice;
754		
755	IV.A.5.c).(6)	locate, appraise, and assimilate evidence from
756		scientific studies related to their patients’ health
757		problems;
758		
759	IV.A.5.c).(6).(a)	<u>Each resident must</u> conduct a comprehensive
760		literature search.
761		
762	IV.A.5.c).(7)	use information technology to optimize learning; and,
763		
764	IV.A.5.c).(8)	participate in the education of patients, families,
765		students, residents and other health professionals.

766		
767	IV.A.5.c).(9)	apply the principles of data collection, data analysis, and
768		data interpretation;
769		
770	IV.A.5.d)	Interpersonal and Communication Skills
771		
772		Residents must demonstrate interpersonal and
773		communication skills that result in the effective exchange of
774		information and collaboration with patients, their families,
775		and health professionals. Residents are expected to:
776		
777	IV.A.5.d).(1)	communicate effectively with patients, families, and
778		the public, as appropriate, across a broad range of
779		socioeconomic and cultural backgrounds;
780		
781	IV.A.5.d).(2)	communicate effectively with physicians, other health
782		professionals, and health related agencies;
783		
784	IV.A.5.d).(3)	work effectively as a member or leader of a health care
785		team or other professional group;
786		
787	IV.A.5.d).(4)	act in a consultative role to other physicians and
788		health professionals;
789		
790	IV.A.5.d).(5)	maintain comprehensive, timely, and legible medical
791		records, if applicable; and,
792		
793	IV.A.5.d).(6)	must counsel and educate patients about diagnosis,
794		prognosis, and treatment.
795		
796	IV.A.5.e)	Professionalism
797		
798		Residents must demonstrate a commitment to carrying out
799		professional responsibilities and an adherence to ethical
800		principles. Residents are expected to demonstrate:
801		
802	IV.A.5.e).(1)	compassion, integrity, and respect for others;
803		
804	IV.A.5.e).(2)	responsiveness to patient needs that supersedes self-
805		interest;
806		
807	IV.A.5.e).(3)	respect for patient privacy and autonomy;
808		
809	IV.A.5.e).(4)	accountability to patients, society and the profession;
810		and,
811		
812	IV.A.5.e).(5)	sensitivity and responsiveness to a diverse patient
813		population, including but not limited to diversity in
814		gender, age, culture, race, religion, disabilities, and
815		sexual orientation.
816		

817	IV.A.5.f)	Systems-based Practice
818		
819		Residents must demonstrate an awareness of and
820		responsiveness to the larger context and system of health
821		care, as well as the ability to call effectively on other
822		resources in the system to provide optimal health care.
823		Residents are expected to:
824		
825	IV.A.5.f).(1)	work effectively in various health care delivery
826		settings and systems relevant to their clinical
827		specialty;
828		
829	IV.A.5.f).(2)	coordinate patient care within the health care system
830		relevant to their clinical specialty;
831		
832	IV.A.5.f).(3)	incorporate considerations of cost awareness and
833		risk-benefit analysis in patient and/or population-
834		based care as appropriate;
835		
836	IV.A.5.f).(4)	advocate for quality patient care and optimal patient
837		care systems;
838		
839	IV.A.5.f).(5)	work in interprofessional teams to enhance patient
840		safety and improve patient care quality; and,
841		
842	IV.A.5.f).(6)	participate in identifying system errors and
843		implementing potential systems solutions.
844		
845	IV.A.6.	<u>Curriculum Organization and Resident Experiences</u>
846		
847	IV.A.6.a)	The program format should <u>must</u> be as follows:
848		
849	IV.A.6.a).(1)	50% of the program (<u>12-month equivalent</u>) must be
850		devoted to direct patient care activities, <u>including inpatient</u>
851		<u>and outpatient care, clinical case conferences, and record</u>
852		<u>reviews;</u>
853		
854	IV.A.6.a).(1).(a)	must have at <u>At least 20% of the required minimum</u>
855		<u>twelve-month equivalent direct patient care activity</u>
856		<u>must in cross-training experience, including</u>
857		<u>continuity of care in the inpatient and outpatient</u>
858		<u>settings focus on patients from birth to 18 years,</u>
859		<u>including continuity of care in inpatient and</u>
860		<u>outpatient settings.</u>
861		
862	IV.A.6.a).(1).(b)	<u>At least 20% of the required minimum twelve-month</u>
863		<u>equivalent direct patient care activity must focus on</u>
864		<u>patients over the age of 18 years, including</u>
865		<u>continuity of care in inpatient and outpatient</u>
866		<u>settings.</u>
867		

- 868 IV.A.6.a).(2) 25% of the program must be devoted to scholarly activities
869 and research; and,
870
- 871 IV.A.6.a).(3) 25% of the program must be devoted to other educational
872 activities.
873
- 874 IV.A.6.a).(3).(a) ~~The “other” category is designed to encourage
875 innovative educational experiences for residents
876 within the program.~~
- 877
- 878 IV.A.6.a).(3).(b) ~~Examples of “other” include, but are not limited to,
879 the following:~~
- 880
- 881 IV.A.6.a).(3).(b).(i) ~~residents attendance at conferences and
882 meetings, including national meetings;~~
- 883
- 884 IV.A.6.a).(3).(b).(ii) ~~educationally valuable committee work
885 within the hospital or with other health
886 organizations;~~
- 887
- 888 IV.A.6.a).(3).(b).(iii) ~~educationally valuable time devoted to
889 hospital administrative requirements; and,
890
891 time spent fulfilling requirements such as
892 Basic Life Support~~
- 893
- 894 IV.A.6.b) ~~All residents must be provided with opportunities to apply
895 immunologic theories, principles, and techniques to the
896 investigation, diagnosis, and treatment of a broad spectrum of
897 allergic and immunologic diseases. The clinical education program
898 requires supervised patient care; rotations through cooperating
899 services;~~
- 900
- 901 IV.A.6.b).(1) ~~must devote 50% (12-month equivalent) of their time to
902 direct patient care activities.~~
- 903
- 904 IV.A.6.c) Resident experiences in direct patient care must include:
- 905
- 906 IV.A.6.c).(1) ~~must receive cross-training in internal medicine and
907 pediatrics, and pediatric and adult allergy and immunology
908 because specialists in allergy and immunology, whatever
909 their primary specialties, are called on to diagnose and
910 treat individuals of all ages;~~
- 911
- 912 IV.A.6.c).(2) ~~training in pediatric and adult allergy and immunology and~~
- 913
- 914 IV.A.6.c).(3) ~~must provide continuing care of pediatric and adult patients
915 with asthma, allergic disorders, immunologic disorders,
916 and immunodeficiency diseases; and,~~
- 917
- 918 IV.A.6.c).(3).(a) Each resident must enter these patients into the

919		ACGME Resident Case Log System;
920		
921	IV.A.6.c).(4)	must have direct patient contact with <u>pediatric children</u> and
922		adults <u>patients</u> with the following diagnoses:
923		
924	IV.A.6.c).(4).(a)	anaphylaxis _;
925		
926	IV.A.6.c).(4).(b)	asthma _;
927		
928	IV.A.6.c).(4).(c)	atopic dermatitis _;
929		
930	IV.A.6.c).(4).(d)	contact dermatitis _;
931		
932	IV.A.6.c).(4).(e)	<u>drug, vaccine, or immunomodulator allergy, or</u>
933		<u>adverse drug reaction</u> allergy to drugs and other
934		biological agents _;
935		
936	IV.A.6.c).(4).(f)	food allergy _;
937		
938	IV.A.6.c).(4).(g)	primary and acquired immunodeficiency _;
939		
940	IV.A.6.c).(4).(h)	ocular allergies _;
941		
942	IV.A.6.c).(4).(i)	rhinitis _;
943		
944	IV.A.6.c).(4).(j)	sinusitis _;
945		
946	IV.A.6.c).(4).(k)	stinging insect allergy _; <u>and,</u>
947		
948	IV.A.6.c).(4).(l)	urticaria and angioedema _;
949		
950	IV.A.6.d)	are strongly encouraged to have direct contact with, or case
951		conference discussions concerning, patients with the following
952		diagnoses:
953		
954	IV.A.6.d).(1)	autoimmune disease
955		
956	IV.A.6.d).(2)	allergic bronchopulmonary aspergillosis
957		
958	IV.A.6.d).(3)	eosinophilic disorders
959		
960	IV.A.6.d).(4)	hypersensitivity pneumonitis
961		
962	IV.A.6.d).(5)	vaccine reactions
963		
964	IV.A.6.d).(6)	mastocytosis
965		
966	IV.A.6.d).(7)	occupational lung disease
967		
968	IV.A.6.d).(8)	vasculitis
969		

970	IV.B.	Residents' Scholarly Activities
971		
972	IV.B.1.	The curriculum must advance residents' knowledge of the basic principles of research, including how research is conducted, evaluated, explained to patients, and applied to patient care.;
973		
974		
975		
976	IV.B.1.a)	The program must provide residents with a structured research experience sufficient to result <u>that results</u> in an understanding of the basic principles of study design, performance <u>(including data collection), data analysis (including statistics and epidemiology), and reporting research results.</u>
977		
978		
979		
980		
981		
982	IV.B.1.b)	attain a working knowledge of research design, statistics, clinical trials, epidemiology, and laboratory research;
983		
984		
985	IV.B.1.c)	apply the principles of data collection, data analysis, and data interpretation
986		
987		
988	IV.B.2.	Residents should participate in scholarly activity.
989		
990	IV.B.2.a)	The program must provide residents with a structured research experience sufficient to result in an understanding of the basic principles of study design, performance, analysis, and reporting.
991		
992		
993		
994	IV.B.2.b)	<u>Under faculty supervision, each resident must design, and</u> conduct, write, and present allergy and/or immunology research in either laboratory-based, epidemiologic, continuous quality improvement, or clinical investigation.
995		
996		
997		
998		
999	IV.B.2.b).(1)	<u>Residents must communicate</u> present their research findings orally and in writing.
1000		
1001		
1002	IV.B.2.c)	design, write, review, or edit research protocols or plans
1003		
1004	IV.B.2.d)	have appropriate supervision for their research activity; and
1005		
1006	IV.B.3.	The sponsoring institution and program should allocate adequate educational resources to facilitate resident involvement in scholarly activities.
1007		
1008		
1009		
1010	V.	Evaluation
1011		
1012	V.A.	Resident Evaluation
1013		
1014	V.A.1.	Formative Evaluation
1015		
1016	V.A.1.a)	The faculty must evaluate resident performance in a timely manner during each rotation or similar educational assignment, and document this evaluation at completion of the assignment.
1017		
1018		
1019		
1020		

1021	V.A.1.b)	The program must:
1022		
1023	V.A.1.b).(1)	provide objective assessments of competence in patient care, medical knowledge, practice-based learning and improvement, interpersonal and communication skills, professionalism, and systems-based practice;
1024		
1025		
1026		
1027		
1028		
1029	V.A.1.b).(2)	use multiple evaluators (e.g., faculty, peers, patients, self, and other professional staff);
1030		
1031		
1032	V.A.1.b).(3)	document progressive resident performance improvement appropriate to educational level; and,
1033		
1034		
1035	V.A.1.b).(4)	provide each resident with documented semiannual evaluation of performance with feedback.
1036		
1037		
1038	V.A.1.b).(5)	use structured checklists and evaluation forms, as encouraged by the Review Committee. The direct observation of resident interactions with patients should be included. Innovation in resident evaluation is encouraged.
1039		
1040		
1041		
1042		
1043	V.A.1.c)	The evaluations of resident performance must be accessible for review by the resident, in accordance with institutional policy.
1044		
1045		
1046		
1047	V.A.1.d)	Innovation in resident evaluation is encouraged.
1048		
1049	V.A.2.	Summative Evaluation
1050		
1051	V.A.2.a)	The program director must provide a summative evaluation for each resident upon completion of the program. This evaluation must become part of the resident's permanent record maintained by the institution, and must be accessible for review by the resident in accordance with institutional policy. This evaluation must:
1052		
1053		
1054		
1055		
1056		
1057		
1058	V.A.2.b)	document the resident's performance during the final period of education, and
1059		
1060		
1061	V.A.2.c)	verify that the resident has demonstrated sufficient competence to enter practice without direct supervision.
1062		
1063		
1064	V.B.	Faculty Evaluation
1065		
1066	V.B.1.	At least annually, the program must evaluate faculty performance as it relates to the educational program.
1067		
1068		
1069	V.B.2.	These evaluations should include a review of the faculty's clinical teaching abilities, commitment to the educational program, clinical knowledge, professionalism, and scholarly activities.
1070		
1071		

- 1072
1073 **V.B.3.** This evaluation must include at least annual written confidential
1074 evaluations by the residents.
1075
- 1076 **V.C.** Program Evaluation and Improvement
1077
- 1078 **V.C.1.** The program must document formal, systematic evaluation of the
1079 curriculum at least annually. The program must monitor and track
1080 each of the following areas:
1081
- 1082 **V.C.1.a)** resident performance;
1083
- 1084 **V.C.1.b)** faculty development;
1085
- 1086 **V.C.1.c)** graduate performance, including performance of program
1087 graduates on the certification examination; and,
1088
- 1089 **V.C.1.d)** program quality. Specifically:
1090
- 1091 **V.C.1.d).(1)** Residents and faculty must have the opportunity to
1092 evaluate the program confidentially and in writing at
1093 least annually, and
1094
- 1095 **V.C.1.d).(2)** The program must use the results of residents'
1096 assessments of the program together with other
1097 program evaluation results to improve the program.
1098
- 1099 **V.C.2.** If deficiencies are found, the program should prepare a written plan
1100 of action to document initiatives to improve performance in the
1101 areas listed in section V.C.1. The action plan should be reviewed
1102 and approved by the teaching faculty and documented in meeting
1103 minutes.
1104
- 1105 **V.C.3.** ~~One outcome measure of the quality of a residency program is the~~
1106 ~~performance of its graduates on the certifying examinations of the~~
1107 ~~American Board of Allergy and Immunology. In its evaluation of residency~~
1108 ~~programs, the Review Committee will take into consideration the~~
1109 ~~information provided by the American Board of Allergy and Immunology~~
1110 ~~regarding resident performance on the certifying examinations. A program~~
1111 ~~will be judged deficient if a program's pass rate is significantly below the~~
1112 ~~national average over a five-year period. At least 70% of the program's~~
1113 ~~graduates from the preceding five years who take the American Board of~~
1114 ~~Allergy and Immunology certifying examination for allergy and~~
1115 ~~immunology for the first time must pass.~~
1116
- 1117 **VI.** Resident Duty Hours in the Learning and Working Environment
1118
- 1119 **VI.A.** Professionalism, Personal Responsibility, and Patient Safety
1120
- 1121 **VI.A.1.** Programs and sponsoring institutions must educate residents and
1122 faculty members concerning the professional responsibilities of

1123 physicians to appear for duty appropriately rested and fit to provide
1124 the services required by their patients.
1125

1126 **VI.A.2.** The program must be committed to and responsible for promoting
1127 patient safety and resident well-being in a supportive educational
1128 environment.
1129

1130 **VI.A.3.** The program director must ensure that residents are integrated and
1131 actively participate in interdisciplinary clinical quality improvement
1132 and patient safety programs.
1133

1134 **VI.A.4.** The learning objectives of the program must:

1135

1136 **VI.A.4.a)** be accomplished through an appropriate blend of supervised
1137 patient care responsibilities, clinical teaching, and didactic
1138 educational events; and,
1139

1140 **VI.A.4.b)** not be compromised by excessive reliance on residents to
1141 fulfill non-physician service obligations.
1142

1143 **VI.A.5.** The program director and institution must ensure a culture of
1144 professionalism that supports patient safety and personal
1145 responsibility. Residents and faculty members must demonstrate an
1146 understanding and acceptance of their personal role in the
1147 following:
1148

1149 **VI.A.5.a)** assurance of the safety and welfare of patients entrusted to
1150 their care;
1151

1152 **VI.A.5.b)** provision of patient- and family-centered care;
1153

1154 **VI.A.5.c)** assurance of their fitness for duty;
1155

1156 **VI.A.5.d)** management of their time before, during, and after clinical
1157 assignments;
1158

1159 **VI.A.5.e)** recognition of impairment, including illness and fatigue, in
1160 themselves and in their peers;
1161

1162 **VI.A.5.f)** attention to lifelong learning;
1163

1164 **VI.A.5.g)** the monitoring of their patient care performance improvement
1165 indicators; and,
1166

1167 **VI.A.5.h)** honest and accurate reporting of duty hours, patient
1168 outcomes, and clinical experience data.
1169

1170 **VI.A.6.** All residents and faculty members must demonstrate
1171 responsiveness to patient needs that supersedes self-interest.
1172 Physicians must recognize that under certain circumstances, the
1173 best interests of the patient may be served by transitioning that

- 1174 patient's care to another qualified and rested provider.
1175
- 1176 **VI.B. Transitions of Care**
1177
- 1178 **VI.B.1. Programs must design clinical assignments to minimize the number**
1179 **of transitions in patient care.**
1180
- 1181 **VI.B.2. Sponsoring institutions and programs must ensure and monitor**
1182 **effective, structured hand-over processes to facilitate both**
1183 **continuity of care and patient safety.**
1184
- 1185 **VI.B.3. Programs must ensure that residents are competent in**
1186 **communicating with team members in the hand-over process.**
1187
- 1188 **VI.B.4. The sponsoring institution must ensure the availability of schedules**
1189 **that inform all members of the health care team of attending**
1190 **physicians and residents currently responsible for each patient's**
1191 **care.**
1192
- 1193 **VI.C. Alertness Management/Fatigue Mitigation**
1194
- 1195 **VI.C.1. The program must:**
1196
- 1197 **VI.C.1.a) educate all faculty members and residents to recognize the**
1198 **signs of fatigue and sleep deprivation;**
1199
- 1200 **VI.C.1.b) educate all faculty members and residents in alertness**
1201 **management and fatigue mitigation processes; and,**
1202
- 1203 **VI.C.1.c) adopt fatigue mitigation processes to manage the potential**
1204 **negative effects of fatigue on patient care and learning, such**
1205 **as naps or back-up call schedules.**
1206
- 1207 **VI.C.2. Each program must have a process to ensure continuity of patient**
1208 **care in the event that a resident may be unable to perform his/her**
1209 **patient care duties.**
1210
- 1211 **VI.C.3. The sponsoring institution must provide adequate sleep facilities**
1212 **and/or safe transportation options for residents who may be too**
1213 **fatigued to safely return home.**
1214
- 1215 **VI.D. Supervision of Residents**
1216
- 1217 **VI.D.1. In the clinical learning environment, each patient must have an**
1218 **identifiable, appropriately-credentialed and privileged attending**
1219 **physician (or licensed independent practitioner as approved by each**
1220 **Review Committee) who is ultimately responsible for that patient's**
1221 **care.**
1222
- 1223 **VI.D.1.a) This information should be available to residents, faculty**
1224 **members, and patients.**

1225		
1226	VI.D.1.b)	Residents and faculty members should inform patients of their respective roles in each patient's care.
1227		
1228		
1229	VI.D.2.	The program must demonstrate that the appropriate level of supervision is in place for all residents who care for patients.
1230		
1231		
1232		Supervision may be exercised through a variety of methods. Some activities require the physical presence of the supervising faculty member. For many aspects of patient care, the supervising physician may be a more advanced resident or fellow. Other portions of care provided by the resident can be adequately supervised by the immediate availability of the supervising faculty member or resident physician, either in the institution, or by means of telephonic and/or electronic modalities. In some circumstances, supervision may include post-hoc review of resident-delivered care with feedback as to the appropriateness of that care.
1233		
1234		
1235		
1236		
1237		
1238		
1239		
1240		
1241		
1242		
1243	VI.D.3.	Levels of Supervision
1244		
1245		To ensure oversight of resident supervision and graded authority and responsibility, the program must use the following classification of supervision:
1246		
1247		
1248		
1249	VI.D.3.a)	Direct Supervision – the supervising physician is physically present with the resident and patient.
1250		
1251		
1252	VI.D.3.b)	Indirect Supervision:
1253		
1254	VI.D.3.b).(1)	with direct supervision immediately available – the supervising physician is physically within the hospital or other site of patient care, and is immediately available to provide Direct Supervision.
1255		
1256		
1257		
1258		
1259	VI.D.3.b).(2)	with direct supervision available – the supervising physician is not physically present within the hospital or other site of patient care, but is immediately available by means of telephonic and/or electronic modalities, and is available to provide Direct Supervision.
1260		
1261		
1262		
1263		
1264		
1265		
1266	VI.D.3.c)	Oversight – the supervising physician is available to provide review of procedures/encounters with feedback provided after care is delivered.
1267		
1268		
1269		
1270	VI.D.4.	The privilege of progressive authority and responsibility, conditional independence, and a supervisory role in patient care delegated to each resident must be assigned by the program director and faculty members.
1271		
1272		
1273		
1274		
1275	VI.D.4.a)	The program director must evaluate each resident's abilities

1276 based on specific criteria. When available, evaluation should
1277 be guided by specific national standards-based criteria.
1278

1279 **VI.D.4.b)** Faculty members functioning as supervising physicians
1280 should delegate portions of care to residents, based on the
1281 needs of the patient and the skills of the residents.
1282

1283 **VI.D.4.c)** Senior residents or fellows should serve in a supervisory role
1284 of junior residents in recognition of their progress toward
1285 independence, based on the needs of each patient and the
1286 skills of the individual resident or fellow.
1287

1288 **VI.D.5.** Programs must set guidelines for circumstances and events in
1289 which residents must communicate with appropriate supervising
1290 faculty members, such as the transfer of a patient to an intensive
1291 care unit, or end-of-life decisions.
1292

1293 **VI.D.5.a)** Each resident must know the limits of his/her scope of
1294 authority, and the circumstances under which he/she is
1295 permitted to act with conditional independence.
1296

1297 **VI.D.5.a).(1)** In particular, PGY-1 residents should be supervised
1298 either directly or indirectly with direct supervision
1299 immediately available.
1300

1301 **VI.D.6.** Faculty supervision assignments should be of sufficient duration to
1302 assess the knowledge and skills of each resident and delegate to
1303 him/her the appropriate level of patient care authority and
1304 responsibility.
1305

1306 **VI.E. Clinical Responsibilities**

1307
1308 The clinical responsibilities for each resident must be based on PGY-level,
1309 patient safety, resident education, severity and complexity of patient
1310 illness/condition and available support services.
1311

1312 **VI.F. Teamwork**

1313
1314 Residents must care for patients in an environment that maximizes
1315 effective communication. This must include the opportunity to work as a
1316 member of effective interprofessional teams that are appropriate to the
1317 delivery of care in the specialty.
1318

1319 **VI.G. Resident Duty Hours**

1320

1321 **VI.G.1. Maximum Hours of Work per Week**

1322
1323 Duty hours must be limited to 80 hours per week, averaged over a
1324 four-week period, inclusive of all in-house call activities and all
1325 moonlighting.
1326

1327	VI.G.1.a)	Duty Hour Exceptions
1328		
1329		A Review Committee may grant exceptions for up to 10% or a
1330		maximum of 88 hours to individual programs based on a
1331		sound educational rationale.
1332		
1333		The Review Committee for Allergy and Immunology will not
1334		consider requests for exceptions to the 80-hour limit to the
1335		residents' work week.
1336		
1337	VI.G.1.a).(1)	In preparing a request for an exception the program
1338		director must follow the duty hour exception policy
1339		from the ACGME Manual on Policies and Procedures.
1340		
1341	VI.G.1.a).(2)	Prior to submitting the request to the Review
1342		Committee, the program director must obtain approval
1343		of the institution's GMEC and DIO.
1344		
1345	VI.G.2.	Moonlighting
1346		
1347	VI.G.2.a)	Moonlighting must not interfere with the ability of the resident
1348		to achieve the goals and objectives of the educational
1349		program.
1350		
1351	VI.G.2.b)	Time spent by residents in Internal and External Moonlighting
1352		(as defined in the ACGME Glossary of Terms) must be
1353		counted towards the 80-hour Maximum Weekly Hour Limit.
1354		
1355	VI.G.2.c)	PGY-1 residents are not permitted to moonlight.
1356		
1357	VI.G.3.	Mandatory Time Free of Duty
1358		
1359		Residents must be scheduled for a minimum of one day free of duty
1360		every week (when averaged over four weeks). At-home call cannot
1361		be assigned on these free days.
1362		
1363	VI.G.4.	Maximum Duty Period Length
1364		
1365	VI.G.4.a)	Duty periods of PGY-1 residents must not exceed 16 hours in
1366		duration.
1367		
1368	VI.G.4.b)	Duty periods of PGY-2 residents and above may be
1369		scheduled to a maximum of 24 hours of continuous duty in
1370		the hospital. Programs must encourage residents to use
1371		alertness management strategies in the context of patient
1372		care responsibilities. Strategic napping, especially after 16
1373		hours of continuous duty and between the hours of 10:00
1374		p.m. and 8:00 a.m., is strongly suggested.
1375		
1376	VI.G.4.b).(1)	It is essential for patient safety and resident education
1377		that effective transitions in care occur. Residents may

1378		be allowed to remain on-site in order to accomplish
1379		these tasks; however, this period of time must be no
1380		longer than an additional four hours.
1381		
1382	VI.G.4.b).(2)	Residents must not be assigned additional clinical
1383		responsibilities after 24 hours of continuous in-house
1384		duty.
1385		
1386	VI.G.4.b).(3)	In unusual circumstances, residents, on their own
1387		initiative, may remain beyond their scheduled period
1388		of duty to continue to provide care to a single patient.
1389		Justifications for such extensions of duty are limited
1390		to reasons of required continuity for a severely ill or
1391		unstable patient, academic importance of the events
1392		transpiring, or humanistic attention to the needs of a
1393		patient or family.
1394		
1395	VI.G.4.b).(3).(a)	Under those circumstances, the resident must:
1396		
1397	VI.G.4.b).(3).(a).(i)	appropriately hand over the care of all
1398		other patients to the team responsible
1399		for their continuing care; and,
1400		
1401	VI.G.4.b).(3).(a).(ii)	document the reasons for remaining to
1402		care for the patient in question and
1403		submit that documentation in every
1404		circumstance to the program director.
1405		
1406	VI.G.4.b).(3).(b)	The program director must review each
1407		submission of additional service, and track
1408		both individual resident and program-wide
1409		episodes of additional duty.
1410		
1411	VI.G.5.	Minimum Time Off between Scheduled Duty Periods
1412		
1413	VI.G.5.a)	PGY-1 residents should have 10 hours, and must have eight
1414		hours, free of duty between scheduled duty periods.
1415		
1416	VI.G.5.b)	Intermediate-level residents should have 10 hours free of
1417		duty, and must have eight hours between scheduled duty
1418		periods. They must have at least 14 hours free of duty after 24
1419		hours of in-house duty.
1420		
1421		First year allergy and immunology residents should be able to
1422		function as residents in the final years of education. However,
1423		some may come to residency with a specialized education and
1424		may only be at the PGY-2 or PGY-3 level. These residents should
1425		be monitored as “intermediate” residents for one year.
1426		
1427	VI.G.5.c)	Residents in the final years of education must be prepared to
1428		enter the unsupervised practice of medicine and care for

1429		patients over irregular or extended periods.
1430		
1431	VI.G.5.c).(1)	This preparation must occur within the context of the 80-hour, maximum duty period length, and one-day-off-in-seven standards. While it is desirable that residents in their final years of education have eight hours free of duty between scheduled duty periods, there may be circumstances when these residents must stay on duty to care for their patients or return to the hospital with fewer than eight hours free of duty.
1432		
1433		
1434		
1435		
1436		
1437		
1438		
1439		
1440	VI.G.5.c).(1).(a)	Circumstances of return-to-hospital activities with fewer than eight hours away from the hospital by residents in their final years of education must be monitored by the program director.
1441		
1442		
1443		
1444		
1445		
1446	VI.G.5.c).(1).(b)	The Review Committee defines such circumstances as: required continuity of care for a severely ill or unstable patient, or a complex patient with whom the resident has been involved; events of exceptional educational value; or, humanistic attention to the needs of a patient or family.
1447		
1448		
1449		
1450		
1451		
1452		
1453	VI.G.6.	Maximum Frequency of In-House Night Float
1454		
1455		Residents must not be scheduled for more than six consecutive nights of night float.
1456		
1457		
1458	VI.G.7.	Maximum In-House On-Call Frequency
1459		
1460		PGY-2 residents and above must be scheduled for in-house call no more frequently than every-third-night (when averaged over a four-week period).
1461		
1462		
1463		
1464	VI.G.8.	At-Home Call
1465		
1466	VI.G.8.a)	Time spent in the hospital by residents on at-home call must count towards the 80-hour maximum weekly hour limit. The frequency of at-home call is not subject to the every-third-night limitation, but must satisfy the requirement for one-day-in-seven free of duty, when averaged over four weeks.
1467		
1468		
1469		
1470		
1471		
1472	VI.G.8.a).(1)	At-home call must not be so frequent or taxing as to preclude rest or reasonable personal time for each resident.
1473		
1474		
1475		
1476	VI.G.8.b)	Residents are permitted to return to the hospital while on at-home call to care for new or established patients. Each episode of this type of care, while it must be included in the 80-hour weekly maximum, will not initiate a new “off-duty
1477		
1478		
1479		

1480 period”.

1481

1482 **VII. Innovative Projects**

1483

1484 **Requests for innovative projects that may deviate from the institutional, common**
1485 **and/or specialty specific program requirements must be approved in advance by**
1486 **the Review Committee. In preparing requests, the program director must follow**
1487 **Procedures for Approving Proposals for Innovative Projects located in the**
1488 **ACGME Manual on Policies and Procedures. Once a Review Committee approves**
1489 **a project, the sponsoring institution and program are jointly responsible for the**
1490 **quality of education offered to residents for the duration of such a project.**

1491

1492
